DST-backed researchers from Pune demonstrate targeted gene-silencing approach that significantly inhibits tumor growth with minimal toxicity
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
Shares issued under ESOP 2008 and MESOP 2018 plans following exercise of vested stock options, in compliance with SEBI disclosure norms
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
The study will run across 18 sites and enroll roughly 200 patients over 24 months
Subscribe To Our Newsletter & Stay Updated
